BDA
6.4.2021 21:47:05 CEST | Business Wire | Press release
The Bermuda Business Development Agency (BDA) will host a virtual panel discussion on Bermuda’s liability market and a Bermuda networking break as part of RIMS, the risk management society® annual conference, a comprehensive risk management event that connects and informs the risk management community. The BDA is proud to be a diamond sponsor of this year’s event, RIMS LIVE, which takes place from April 19–30.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210406006077/en/
The panel, titled “Changes and Trends in Liability Risk,” will be held on April 22 from 2–3 p.m. ADT. The session will feature Judy Gonsalves, division president at Chubb Bermuda; Saadia Savory, vice president and head of casualty Bermuda at Aspen Insurance; and Kirsten Beasley, interim head, Willis Towers Watson Bermuda. Moderated by Jasmine DeSilva, the BDA’s business development manager for risk and insurance solutions, the panel will explore the current state of the liability market, emerging trends, and the Bermuda market’s response.
“RIMS is the largest risk event of the year — it is a staple in the calendar and the Bermuda market has proudly attended for more than 35 years,” BDA’s CEO Roland Andy Burrows said. “The BDA and Bermuda are extensively committed to supporting and growing the risk management industry here, and participating in the RIMS annual conference is a key part of that. Bermuda continues to work hard to remain at the forefront of commercial trends and drives innovation forward as one of the world’s most important insurance and reinsurance hubs.”
For those who want to connect with Bermuda and the BDA, or find out more, the BDA will host a virtual booth where delegates can learn more about the market, view videos, and engage in live chat. Delegates can also schedule video meetings.
On a lighter note, the BDA will be bringing Bermuda to the attendees during the “Take a Break in Bermuda” networking event on April 20 at 4:30 p.m. ADT, providing an opportunity to hear from the Premier of Bermuda, the Hon. E. David Burt, JP, MP; Bermuda’s Minister of Finance, the Hon. Curtis Dickinson, JP, MP; and BDA CEO Roland Andy Burrows, who will all be speaking from the beautiful Hamilton Princess & Beach Club.
Also from the Hamilton Princess, Jasmine DeSilva and Andrew Holmes, Bermuda brand director for Goslings, will make Bermuda’s famous Rum Swizzle cocktail in Sheila Gosling’s Maytag vintage washing machine from 1964 — the same appliance Bermuda’s late social queen used to prepare drinks in the 1960s. The BDA will also announce the winner of an all-expenses paid trip to Bermuda, including a stay at the Hamilton Princess.
For more information on RIMS and to register for the conference, click here . To schedule a meeting with a BDA team member, please email jasmine@bda.bm or olivia@bda.bm . For more information on the BDA, click here .
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406006077/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom